Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
grade F 12.29 4.60% 0.54
CLLS closed up 4.6 percent on Friday, August 16, 2019, on 1.24 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLLS trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 4.60%
Narrow Range Bar Range Contraction 4.60%
NR7 Range Contraction 4.60%
Lower Bollinger Band Walk Weakness 4.60%
New 52 Week Low Weakness 4.60%
Wide Bands Range Expansion 4.60%
Below Lower BB Weakness 4.60%

Older signals for CLLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Multiple Myeloma Leukemia Glioblastoma Chronic Lymphocytic Leukemia Hematologic Malignancies Solid Tumor Oncogenes Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues Acute Lymphoblastic Leukemia Cellectis
Is CLLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 29.97
52 Week Low 11.7
Average Volume 124,407
200-Day Moving Average 18.0328
50-Day Moving Average 14.8892
20-Day Moving Average 13.986
10-Day Moving Average 12.96
Average True Range 0.7113
ADX 28.45
+DI 21.3364
-DI 36.4035
Chandelier Exit (Long, 3 ATRs ) 13.7261
Chandelier Exit (Short, 3 ATRs ) 13.8339
Upper Bollinger Band 16.3442
Lower Bollinger Band 11.6278
Percent B (%b) 0.14
BandWidth 33.722294
MACD Line -0.8544
MACD Signal Line -0.6781
MACD Histogram -0.1763
Fundamentals Value
Market Cap 439.85 Million
Num Shares 35.8 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -5.34
Price-to-Sales 23.25
Price-to-Book 4.09
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.27
Resistance 3 (R3) 13.28 12.98 13.10
Resistance 2 (R2) 12.98 12.73 12.97 13.05
Resistance 1 (R1) 12.63 12.57 12.81 12.62 12.99
Pivot Point 12.33 12.33 12.41 12.32 12.33
Support 1 (S1) 11.98 12.08 12.16 11.97 11.59
Support 2 (S2) 11.68 11.92 11.67 11.53
Support 3 (S3) 11.33 11.68 11.48
Support 4 (S4) 11.32